Comparison / Study ID (number of participants)	Outcome	RR	95% CI lower limit	95% CI upper limit
rATG: single 6 mg/kg versus 4 x 1.5 mg/kg doses (same total dose)
Stevens 2008 (142)	Death at 6 months	0.34	0.01	8.27
	Graft loss (all cause) at 6 months	0.21	0.01	4.21
	Acute rejection	0.69	0.26	1.83
	Delayed graft function	2.40	0.65	8.91
	Malignancy/PTLD	0.21	0.01	4.21
	BKV	0.15	0.01	2.79
	Severe febrile reaction (anaphylaxis requiring ICU)	1.03	0.15	7.10
	Serum sickness	0.21	0.01	4.21
	NODAT	0.82	0.47	1.42
ATG: 2 x3 mg/kg versus 4 x 1.5 mg/kg doses (same total)
Buchler 2013 (17)	**	‐	‐	‐
ATG: adjusted for CD3 count versus fixed dose of 15 mg/kg/d
Abouna 1995 (45)	Death at 2 years	0.96	0.06	14.37
	Graft loss (all cause) 2 years	0.72	0.18	2.85
	Acute rejection	0.96	0.5	1.84
	Leucopenia	0.36	0.11	1.18
	Thrombocytopenia	0.14	0.01	2.51
	Viral infection (all cause)	0.96	0.15	6.21
	Bacterial infection (all cause)	0.64	0.21	1.96
ATG: adjusted by CD3 count versus adjusted by total lymphocytes
Ata 2013 (21)	**	‐	‐	‐
ATG: standard (3.75 mg/kg total) versus low dose (2.25 mg/kg total)
Grafals 2014 (43)	Acute rejection at 1 year	0.57	0.12	2.81
	Leucopenia	0.69	0.31	1.56
	Severe infection	0.77	0.14	4.14
	CMV infection	0.23	0.01	4.50
	BKV infection	0.38	0.02	8.86
	Death at 1 year	8.00	0.44	146.08
	Delayed graft function	3.07	0.94	10.02
	Malignancy at 1 year	2.30	0.23	23.51
	PTLD at 1 year	0 events	not estimable
	Graft function at 1 year (SCr, µmol/L)	6.00*	1.07	10.93
OKT3: standard dose (5 mg) versus low dose (2 mg)
Norman 1993a (26)	Death at 1 year	0 events	not estimable
	Graft loss at 1 year	3	0.13	67.51
	Acute rejection	0.2	0.01	3.8
	Delayed graft function	1.25	0.43	3.63
	CMV	4	0.51	31.13
	Herpes Simplex virus	0.5	0.05	4.86
	Bacterial	0.86	0.4	1.86
	Fungal	1	0.16	6.07
	Malignancy	4.72	0.23	96.59
OKT3: standard dose (5 mg) versus high dose (10 mg)
Abramowicz 1994 (29)	Death at 3 months	0 events	not estimable
	Graft loss at 3 months	4.69	0.24	89.88
	Acute rejection to 3 months	0.47	0.1	2.16
	Delayed graft function	0.93	0.34	2.54
ALG: low versus high dose
Sakhrani 1992 (83)	Death at 1 year	0.89	0.41	1.97
	Acute rejection	0.86	0.48	1.55
	Leucopenia	0.5	0.18	1.41
	Severe infection	1.05	0.52	2.11
ALG: 14 days versus 7 days
Grundmann 1987 (100)	Death 1 year	0 events	not estimable
	Graft loss (all cause) 1 year	0.29	0.06	1.31
	Acute rejection	0.5	0.05	5.34
	Delayed graft function	0.62	0.28	1.35
	Pneumonia	3	0.13	71.92
	Wound infection	0 events	not estimable
	Treatment stopped due to side effects	63	3.96	1002.01
	Graft function at 1 year (SCr, µmol/L)	‐35.4*	‐78.72	7.92
ALG: high versus low potency
Thomas 1977 (71)	Acute rejection at 3 months	4.14	1.55	11.00
	Graft loss at 1 year	2.53	1.30	4.90